What is CJC-1295 with DAC?
A long-acting GHRH analog that binds albumin; human studies showed GH and IGF-1 rises lasting days after one injection.
CJC-1295 with DAC in the library · Growth Hormone Secretagogues · Human Trials · What are peptides?
0 registered trials · 2 indexed papers · 15 human / 7 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
CJC-1295 with DAC is described as a modified GHRH(1-29) attached to a reactive "drug affinity complex" that bonds to albumin in the blood, stretching its half-life to roughly 6 to 8 days.
It was developed by ConjuChem; clinical development stopped in 2006 after a trial death that the company said was unrelated to the drug.
Mechanism (as described)
- Continuous GHRH-receptor stimulation raised average GH and IGF-1 for days, while the normal pulsatile pattern of GH release was reported to persist (Ionescu et al., 2006).
Evidence (as described)
- No outcome trials (body composition, function) were completed.
Status
Never approved; development halted in 2006.
Peer-reviewed studies (2)
| Paper | Authors | Journal | Year | Type |
|---|---|---|---|---|
| Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295 (with DAC), a long-acting GH-releasing hormone analog | Ionescu M et al. | The Journal of clinical endocrinology and metabolism | 2006 | Clinical Trial |
| Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 (with DAC), a long-acting analog of GH-releasing hormone, in healthy adults | Teichman SL et al. | The Journal of clinical endocrinology and metabolism | 2006 | Randomized Controlled Trial |
More cited research
- Activation of the GH/IGF-1 axis by CJC-1295 (with DAC), a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects (2009, human observational)
- Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS (2016, human observational)
- Once-daily administration of CJC-1295 (with DAC), a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse (2006, animal)
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 (no DAC) a (2005, animal)
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine (2026, animal)
- Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth (2009, animal)
Conditions researched
Related compounds
- CJC-1295 (no DAC), Mod GRF 1-29
- CJC-1295 (no DAC) (with/without DAC) + Ipamorelin
- GHK (Copper-Free)
- Ipamorelin
- ACTH (Corticotropin)
- BNP (Nesiritide)
- BPC-157
- CRH (Corticotropin-Releasing Hormone)
- Carnosine
- Cosyntropin
FAQ
How many registered human trials study CJC-1295 with DAC?
The PeptideWhiz trial index lists 0 registered trials for CJC-1295 with DAC.
How much published research exists on CJC-1295 with DAC?
The PeptideWhiz paper index links 2 PubMed papers to CJC-1295 with DAC; by study type, 15 human and 7 animal studies.
Which conditions is CJC-1295 with DAC researched for?
Lyme disease & chronic infections, Multiple sclerosis.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).